Member Info for Jimmybob

The estimated NPV10 for West Newton Kirkham abbey gas was put at $247m, the Cadeby formation oil, at $850m, 25% economic interest to RBD, then WN is worth $274m or £216m or 5.6p per share. Then there is the rest of the licence, new licences from Ratlin announced last week, California production figures are due any time and Parta about to be drilled, plus Colter South. This could easily multi bag from here. Patience is key;-). JB

Is it oil or condensate? What the difference is price anyone? The interview hints of condensate? JB

Interesting there was not much movement in our SP during the drilling of West Newton, the news will filter through. So much to come here, let’s hope this is the start of that trickle North! JB

Sell on news gang soon to clear then hopefully we can tick up to our true value! JB

Sell on news brigade, extended well test and flow rates due Q3 so not imminent? Maybe a few moving on to pastures new? JB

The sign says that the road is closed for 21 days due to public safety reasons and the close facility of testing to the road. JB

Hi Ivy, sorry about your loss, I am sitting here with my cockerpoo. I too have lost 4 legged best friends, it’s certainly leaves a big hole in your family/life. Take care, JB

Yes always 2 sides, glass half empty or full etc. I do feel for everyone here, it’s not good at all but not necessarily the end of the road. I understand people growing in the towel. But this maybe the bottom. Things can move quickly as we know. JB

People here are understandably very angry about this situation and are gunning for the CEO, the trolls are having a field-day as the company appears in disorder. I am sitting on a large paper loss, as I am sure the majority of holders are. Just to throw in some balance, the trial protocol was blinded and agreed with the FDA and so the observation of the prolonged elevated levels was unexpected. The CEO may have put forward arguments post the CRL follow up meeting, to try and convince the Agency to allow a post approval study. The company may not have got the response that this was not acceptable until it was included in the minutes, several people here are making the assumption this was discussed at the meeting and that option rejected at the meeting, implying that the CEO is withholding the truth. This may not be the case! The FDA are also a guiltily party here, they are the gatekeeper, but are also supposed to help and partner with companies to achieve approval. If a company follows their agreed protocol and the data and the study appears successful, then the company will have been expecting that the approval is a formality. I think that’s what may have happened here. I understand the frustration and the anger here placed at the CEO, this is why he gets paid the big bucks. But now is the time more than ever, for him to earn his keep. Let’s see if he can get the funding we need, realise the potential and value of this asset, gain approval and realise this treatment for suffering patients. Good luck to all, JB

Wonder if it would be possible to bring some of the 1.8% of subjects that had the enzyme issue back in from the phase III study and follow their enzyme levels post a further course of the drug? Or even re-assess to see if their enzyme levels are completely normal? This is cutting corners to clean up the gap in the first study, but should be the kind of strategy that the team out to the FDA to avoid another large study? JB

Slight recovery over on the NASDAQ let’s hope we pick up from
Where they leave off tomorrow. JB

Let’s hope it’s a relatively small short term study on a relatively accessible patient population. These studies don’t always cost the earth, however we don’t know what the request is and hence the size, cost and risk of the ask. I hope the company does and gives us some answers at 1.00. JB

It noting really to do with the balance of numbers for every buyer there must be a seller. The value is driven by what people are prepared to accept and pay plus the spread which is the cream for the m and ms which are the only winners as usual! Jb

Well got a few more at 4.35p. Good luck all. JB

The company will have an idea of the issue from the minutes and the next steps will be to formulate the protocol to put to the FDA in a follow up meeting. The protocol will then be agreed/negotiated between the company and the FDA. The trial can then be planned and initiated. We don’t know how long it would take or the level of complexity, it could even be on healthy volunteers for all we know. Anyhow we are all just guessing until we get a steer from the company and Agency.

Patience, the guidance on the timing from the FDA is only just up. It’s not firmIt may be a week or so longer with them being busy from the shutdown. Just chill and wait. JB

https://www.proactiveinvestors.co.uk/companies/amp/news/221389

The theory of intelligence; “Well you see, it’s like this… A herd of buffalo can only move as fast as the slowest buffalo. And when the heard is hunted, it is the slowest and weakest buffalo at the back that are killed first. This natural selection is good for the herd as a whole. because the general speed and health of the whole group keeps improving by the regular killing of the weakest members. In much the same way, the human brain can only operate as fast as the slowest brain cells. Now, as we know, excessive intake of alcohol kills brain cells. But naturally, it attacks the slowest and weakest brain cells first. In this way, the regular consumption of beer eliminates the weaker brain cells, making the brain a faster and more efficient machine. And that, Norm, is why you always feel smarter after a few beers.”

Have a great weekend! JB

PS my “version of the facts” as you say, come from my interactions with the FDA and being present in these meetings. I have experience in these review meetings including NDAs, BLAs and drug device combos. JB